

23446

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 032219WOTM	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/HU2004/000077	International filing date (day/month/year) 16/07/2004	(Earliest) Priority Date (day/month/year) 16/07/2003
Applicant RICHTER GEDEON VEGYESZETI GYAR RT.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ **Certain claims were found unsearchable** (See Box II).

3. ☐ **Unity of invention is lacking** (see Box III).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regards to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ as selected by this Authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.

- b. ☒ none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/42 C07D231/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOSH J. YUAN ET AL.: "Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human" DRUG METABOLISM AND DISPOSITION, vol. 30, no. 9, 2002, pages 1013-1021, XP002311618	1,2,6,7
Y	cited in the application abstract; figure 5 page 1018, column 2, paragraph 2 ----- -/--	1-7, 14-21

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

21 December 2004

Date of mailing of the international search report

20/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Molina de Alba, J

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOHN J. TALLEY ET AL.: "4-'5-Methyl-3-phenylisoxazol-4-yl!-benzen esulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2" J.MED.CHEM., vol. 43, 2000, pages 775-777, XP002311619 page 776, column 2, paragraph 2 - paragraph 3; compounds 2,3 -----	1-21
Y	HERBERT T. NAGASAWA ET AL.: "Carbethoxylating agents as inhibitors of aldehyde dehydrogenase" J.MED.CHEM., vol. 38, 1995, pages 1872-1876, XP002311620 page 1875, column 1, last paragraph -----	8-13
Y	MAURICE L. MOORE ET AL.: "Substituted sulfanilamides. III. N4-Acyl-N1-hydroxy derivatives" J.AM.CHEM.SOC., vol. 62, 1940, pages 2097-2099, XP002311621 page 2098, column 1, paragraph 2 - paragraph 3 -----	8-13
A	JI Y. ZHANG ET AL.: "Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice" DRUG METABOLISME AND DISPOSITION, vol. 31, no. 4, April 2003 (2003-04), pages 491-501, XP002311622 page 501, column 1, last paragraph - column 2, paragraph 1; figure 8 -----	1-21
A	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SARAPA, NENAD ET AL: "Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization" XP002311623 retrieved from STN Database accession no. 2003:753917 abstract & JOURNAL OF CLINICAL PHARMACOLOGY , 43(9), 974-982 CODEN: JCPCBR; ISSN: 0091-2700, 2003, -----	14-21